Pantherna Therapeutics is a Germany-based biotechnology company developing messenger RNA (mRNA) medicines. The company designs mRNA drug candidates and employs lipid nanoparticle (LNP) delivery technologies to enable efficient delivery of therapeutic payloads.
Pantherna’s research focuses on serious diseases with high unmet medical need, including respiratory and vascular indications. Its programs are in preclinical development, with the goal of advancing candidates toward clinical studies, supported by collaborations with specialized development and manufacturing partners.